arrow
A

A. Sarah Walker

University of Oxford
H指数:82
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical validation of an optimised metagenomic nanopore sequencing method for detecting viral respiratory pathogens

一种优化的宏基因组纳米孔测序方法在检测病毒性呼吸道病原体中的临床验证

2026-08-220
OAAI
Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD-CAA prevention (KD-CAAP) trial

多中心、随机、开放标签、盲法终点评估试验:比较糖皮质激素联合静脉注射免疫球蛋白(IVIG)和阿司匹林与IVIG和阿司匹林预防川崎病(KD)冠状动脉瘤(CAA)的效果——川崎病冠状动脉瘤预防(KD-CAAP)试验

2026-07-130
OAAI
Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda

乌干达接受二线抗逆转录病毒治疗96周后,人类免疫缺陷病毒感染者儿童的骨矿物质密度纵向变化

2026-02-170
PRE
Evaluation of SARS-CoV-2 lateral flow device sensitivity: a comparison of systematic laboratory assessments with manufacturer-reported sensitivity

SARS-CoV-2侧流装置敏感度评估:系统实验室评估与制造商报告敏感度的比较

2025-08-270
OAAI
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

MEDI0618(一种pH依赖性的靶向PAR2的单克隆抗体)在偏头痛预临床模型中的疗效

BRAIN
IF11.7
2025-02-280
PRE
No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia (vol 88, 106161, 2024)

无证据表明,在治疗社区获得性肺炎的医院疗法中,使用阿莫西林与使用阿莫西林-克拉维酸(co-amoxiclav)在死亡率方面存在差异(卷88,106161,2024)

2024-12-010
PRE
How, why and when are delayed (back-up) antibiotic prescriptions used in primary care? A realist review integrating concepts of uncertainty in healthcare

如何,为什么和何时延迟 (备份) 抗生素处方用于初级保健?整合医疗保健中不确定性概念的现实主义评论

2024-10-141
OAAI
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification

通过时空回归和后分层提高英国全国新型冠状病毒肺炎感染调查的代表性

2024-06-241
OAAI